MannKind gets out the ax (again) as Afrezza sales fizzle; Bristol-Myers gains new Opdivo/Yervoy approval at the FDA;

@FierceBiotech: Fierce's coverage of the Martin Shkreli saga. More | Follow @FierceBiotech

@JohnCFierce: Ladies and gentlemen, the 2015 Fierce 15. Special report | Follow @JohnCFierce

> With sales of Afrezza barely registering at Sanofi, MannKind ($MNKD) has triggered its third round of layoffs, with the ax falling throughout its organization. MannKind's shares dropped to a 52-week low--around the $3 mark--as the news spread. Story

> Bristol-Myers Squibb ($BMY) won FDA approval for a combination of Opdivo and Yervoy to treat metastatic melanoma. Release

Medical Device News

@FierceMedDev: From FierceDrugDelivery: Intarcia buys Phoundry in search of additional diabetes drugs for its subdermal drug pump. Story | Follow @FierceMedDev

@VarunSaxena2: Study: Oraya radiation tech reduces need for eye injections in AMD patients. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FiercePharma: New Hampshire AG launches investigation into opioid marketing. Article | Follow @EmilyWFierce

> Neuravi ready to take on Medtronic, Stryker in burgeoning market for devices to fight stroke. More

Pharma News

@FiercePharma: Sun Pharmaceutical's Shanghvi drops from top spot in Forbes India rich list. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: ICYMI: Merck KGaA counts on Latin America to power consumer-health future. Article | Follow @CarlyHFierce

> Express Scripts: Strict prior-auth moves keep a tight lid on PCSK9 sales. Story

> Novartis stacks up more data for lucrative Cosentyx expansion. Article

Vaccines News

> Novavax's RSV jab protects infants in PhII, nets $89M Gates Foundation grant. Article

> Advaxis targets HER2 cancers with first-in-human vaccine trial. Story

> BiondVax, EU's UNISEC team up for universal flu jab PhIIb. More

> PRA Health joins with clinical research network to improve vaccine studies. Item

> NewLink wins $26.1M in government funding to advance Ebola vaccine. Report

CRO News

> Frontage doubles its bioanalytics space. Item

> Accelovance snags another Big Pharma cancer vet to boost its onco profile. Report

> PRA partners up to accelerate vaccine R&D. More

> Patheon rebrands with a $100M IPO in the works. Story

> Chiltern expands in diabetes after a big buyout. Article

Pharma Manufacturing News

> Siegfried completes $302M deal for BASF API plants. News

> EPA presents Pfizer with $194M bill to cleanup former American Cyanide site. Report

> Abbott said to expand manufacturing, other operations in India. Story

> Will a desktop device that synthesizes lidocaine revolutionize pharma manufacturing? More

> Hovione set to expand its NJ facility and add new spray dryer. Article

Pharma Asia News

> China slaps Fosun Pharma unit with small fine for anti-monopoly violations. News

> Singapore's Biosensors launches sales of BMX-J stent in key Japan market. More

> Australia's Paranta Biosciences raises A$7M for PhI of cystic fibrosis candidate. Report

> China biotech CARsgen inks deal with Shanghai Cancer Institute on candidate focus. Story

> MSF campaigns at UN summit meeting to ease pressure on India's drug IP policies. Article

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.